Literature DB >> 26361138

Cardiac amyloidosis: pathology, nomenclature, and typing.

Joseph J Maleszewski1.   

Abstract

Amyloidosis is an increasingly recognized cause of heart disease, caused by the deposition of misfolded protein within the heart. These proteins may deposit systemically and include the heart or deposit only within the heart muscle itself. In either case, cardiac symptoms may be the primary manifestation. The diagnosis is usually made by the pathologist identifying amyloid within a tissue sample. The diagnosis, however, does not end with such visual recognition of the presence of amyloid. Newer generation pharmacotherapeutic agents that are protein specific necessitate a closer evaluation to determine the type of protein being deposited and accurately conveying this to the treating clinician. Herein, the gross and histopathologic features of cardiac amyloidosis are reviewed along with a review of amyloid typing strategies (both direct and indirect) that may be employed in the diagnostic workup as well as the nomenclature standards for reporting.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Infiltrative cardiomyopathy; Proteomics; Restrictive cardiomyopathy

Mesh:

Substances:

Year:  2015        PMID: 26361138     DOI: 10.1016/j.carpath.2015.07.008

Source DB:  PubMed          Journal:  Cardiovasc Pathol        ISSN: 1054-8807            Impact factor:   2.185


  32 in total

Review 1.  Advances in Treatment of Cardiac Amyloid.

Authors:  Cherie N Dahm; R Frank Cornell; Daniel J Lenihan
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

Review 2.  Microvascular dysfunction in infiltrative cardiomyopathies.

Authors:  Ornella Rimoldi; Francesco Maranta
Journal:  J Nucl Cardiol       Date:  2017-07-11       Impact factor: 5.952

Review 3.  New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.

Authors:  Stefano Perlini; Roberta Mussinelli; Francesco Salinaro
Journal:  Curr Heart Fail Rep       Date:  2016-12

4.  Heavy and light chain (AHL)-type cardiac amyloidosis: first histopathologic-proven case illustrating involvement of the heart.

Authors:  Miroslav Sekulic; Simona Pichler Sekulic; Astrid Weins
Journal:  Virchows Arch       Date:  2020-05-09       Impact factor: 4.064

Review 5.  Recent advances in the noninvasive strategies of cardiac amyloidosis.

Authors:  Lei Zhao; Quan Fang
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

Review 6.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

Review 7.  Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis.

Authors:  Deepa M Gopal; Frederick L Ruberg; Omar K Siddiqi
Journal:  Curr Heart Fail Rep       Date:  2019-10

8.  Systemic immunoglobulin light-chain amyloidosis presenting hematochezia as the initial symptom.

Authors:  Tetsuo Kon; Naoki Nakagawa; Fumitsugu Yoshikawa; Kazunao Haba; Nagako Kitagawa; Michihiro Izumi; Setsuo Kumazaki; Satoshi Ishida; Ryuichi Aikawa
Journal:  Clin J Gastroenterol       Date:  2016-06-18

9.  Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis.

Authors:  Patrick Martineau; Vincent Finnerty; Geneviève Giraldeau; Sébastien Authier; Francois Harel; Matthieu Pelletier-Galarneau
Journal:  J Nucl Cardiol       Date:  2019-03-04       Impact factor: 5.952

10.  Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases.

Authors:  Pablo Garcia-Pavia; Claudio Rapezzi; Yehuda Adler; Michael Arad; Cristina Basso; Antonio Brucato; Ivana Burazor; Alida L P Caforio; Thibaud Damy; Urs Eriksson; Marianna Fontana; Julian D Gillmore; Esther Gonzalez-Lopez; Martha Grogan; Stephane Heymans; Massimo Imazio; Ingrid Kindermann; Arnt V Kristen; Mathew S Maurer; Giampaolo Merlini; Antonis Pantazis; Sabine Pankuweit; Angelos G Rigopoulos; Ales Linhart
Journal:  Eur Heart J       Date:  2021-04-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.